PMPaul D. Mintz

Paul D. Mintz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul D. Mintz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • OBITUARY: John Bernard Henry, MD: 1928-2009

    by Leonard Boral, Paul D. Mintz, Charles Rouault

  • Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

    by P D Mintz, G Wehrli

    The irradiation of cellular blood components to prevent transfusion-associated (TA)-GVHD is an established practice in the developed world. Susceptible patients include those who are immunosuppressed, fetuses, very premature neonates and patients who have an increased likelihood of possessing one HLA haplotype for which the blood component donor is homozygous. Problems and challenges associated with blood component irradiation include transfusion delay, cost, failure to irradiate when indicated, increased potassium accumulation in and decreased shelf life of RBC units, reduced RBC recovery and, in the United States, substantial and onerous security requirements for cesium-137 source irradiators and their operators. Microbial contamination of blood components can pose life-threatening risks for transfusion recipients. Donor history screening and infectious disease testing are a reactive response and expensive, as well as an imperfect and incomplete means for preventing these infectious risks. In response to these threats, pathogen reduction technologies have been developed. Two such innovations (INTERCEPT, Cerus Corporation, Concord, CA, USA; and Mirasol, CaridianBCT Biotechnologies, Lakewood, CO, USA) are approved for clinical use in many countries, though not in the United States. These processes have been shown to effectively prevent proliferation of nucleic acid-containing microbes, thereby providing broad protection against transfusion-transmitted infection. These technologies have also been shown to prevent the replication of WBC. In this report, we review the substantial in vitro, clinical trial and clinical practice observational evidence that non-irradiated INTERCEPT- and Mirasol-treated cellular blood components do not cause TA-GVHD. Implementation of these processes precludes the necessity for irradiating cellular blood components to prevent TA-GVHD.


  • Double standard for double ABO grouping?

    by Paul D. Mintz, Walter H. Dzik


  • Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

    by Paul D. Mintz, Nathan M. Bass, Lawrence D. Petz, Randolph Steadman, Michael Streiff, Jeffery McCullough, Sandra Burks, David Wages, Sally Van Doren, Laurence Corash

    An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP.


  • Bacterial detection and extended platelet storage: The next step forward

    by Richard J. Benjamin, Paul D. Mintz


  • Assessment of the correlation of platelet morphology with in vivo recovery and survival

    by Paul D. Mintz, Garth Anderson, Nancy Avery, Pamela Clark, Robert F. Bonner


    • 1 January 1998
      • Vol. 8  (2) , 103-16

    Fibrin sealant: an evaluation of methods of production and the role of the blood bank.

    by R R Gammon, N Avery, P D Mintz

    Blood banks can prepare fibrin sealant by several methods. Allogeneic components allow for banking of the fibrinogen concentrate for immediate use. Autologous components eliminate the risk of transfusion-transmitted disease to the recipient, but not necessarily to the preparer. Ethanol and ammonium sulfate precipitation of fibrinogen concentrate allow use of autologous blood and fast preparation (less than 90 minutes). Cryoprecipitation from liquid plasma is adequate, conserving fresh frozen plasma. Cryoprecipitation by the "freeze-thaw" method has been reported to have the highest fibrinogen yield (7840 mg/dL +/- 1800 mg/dL), whereas ammonium sulfate precipitation has been reported to have the highest bonding strength (41 g/cm2 10 minutes after thrombin addition). Cost, storage, preparation time, and transfusion-transmitted disease all play a role in choice of method.


  • Rejuvenation of irradiated AS-1 red cells

    by L.H. Samuel, G. Anderson, P.D. Mintz


    • 1 July 1994
      • Vol. 24  (4) , 339-45

    Effect of oxygen and temperature on the potassium efflux of irradiated, stored red blood cells.

    by G Anderson, P D Mintz

    Gamma irradiation of blood is performed to prevent transfusion-associated graft-versus-host disease and can result in an accelerated efflux of intracellular potassium (K+). The oxygen content of the blood and the temperature at which the irradiation is carried out are two variables reported to affect this shift; they were investigated in two separate studies. Study A-Four units of AS-5 red blood cells were each split equally into four transfer bags. One set of transfer bags was stored at 4 degrees C for 42 days (Control), the second set (IRR) was irradiated and stored. The third and fourth groups were oxygenated; the third set (+O2) was placed at 4 degrees C. The fourth set (IRR+O2) was irradiated, then stored. Supernatant K+ and hemoglobin increased in the IRR + O2 group over IRR and Control, +O2 did not rise compared to Control. Study B-Six units of CPDA-1 whole blood were each equally separated into four transfer bags. The first set of bags was placed at 4 degrees C, the second set was irradiated and then stored (IRR). The third group of bags was irradiated and given an 8-hour 22 degrees C incubation prior to storage at 4 degrees C (IRR-22). The fourth set was irradiated, placed at 37 degrees C for 2 hours, then stored. Supernatant K+ was lower during the first 7 days of storage for the IRR-22 and IRR-37 groups compared to IRR, but these increased to IRR levels by day 35. Irradiation of blood products results in an accelerated K+ shift that can be exacerbated by the presence of oxygen. The injury can be partially and temporarily corrected by a post-irradiation incubation at 22 degrees C or 37 degrees C.